The 2026 Healthtech Messaging Index
BrightInsight
brightinsight.com·scored August 23, 2026
30/38
Approaching
Close. The bones are good. A few targeted fixes on the weakest signals would push BrightInsight into magnetic territory.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for Patient persistence and therapy adherence platform for pharma brands, it named:
Buyer we put in the prompt: Brand General Manager or VP of Patient Services at a mid-to-large pharmaceutical or biopharma company launching or managing a novel therapy. Both the buyer and the category were inferred from BrightInsight’s homepage alone. The model had no web access.
BrightInsight was not on the list.
A buyer who asked AI this question got 8 names and moved on. BrightInsight never came up.
We asked AI who it recommends for "Brand General Manager or VP of Patient Services at a mid-to-large pharmaceutical or biopharma company launching or managing a novel therapy" looking for "Patient persistence and therapy adherence platform for pharma brands". It named Adheris Health, Lash Group, AssistRx, Novu Health, Aktana. You did not appear. AI can't recommend what it can't clearly understand.
Overall assessment
BrightInsight's biggest strength is its sharp, owned narrative: 'patient persistence solution' and 'persistence crisis' are coined terms with quantified stakes ($500B+) and real proof (Sanofi -4% discontinuation), making this homepage unusually AI-quotable and distinct. The biggest gap is the absence of a buyer journey ... no named process, no role-specific entry points, no acknowledgment of alternatives ... so a qualified buyer who arrives intrigued has no structured path to convert beyond a generic 'Contact us.'
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, or 'do nothing' option anywhere on the page.”
The page never acknowledges what buyers might do instead ... no competitors named, no 'do nothing' cost, no comparison to CRM or hub services ... alternatives are completely absent.
All 19 signals, scored 0 to 2.
Total 30/38
Narrative Clarity
8 signals
- 2
01The 7-Second Test
“BrightInsight is the patient persistence solution that predicts and prevents therapy drop-off ... before it happens.”
Within 7 seconds, a stranger can identify the pharma brand audience, the problem (patients quitting therapy), and the solution angle (predict and prevent drop-off) ... the hero is specific and plain-language enough to pass the caveman test.
- 2
02Rebellion / Movement
“the persistence crisis steals health from patients and $500B+ in annual value from brands every year”
The page names a specific, quantified enemy ... the 'persistence crisis' and the systemic failure of 'existing systems' ... giving the company a clear villain to push against.
- 2
03Owned Language & Category
“'patient persistence solution' ... 'persistence crisis' ... 'therapy drop-off' ... 'patient lifetime value'”
BrightInsight owns the term 'patient persistence solution' and coins 'persistence crisis' as a named category frame that an AI could quote back and attribute specifically to this company.
- 1
04ICP Clarity
“Creating patient lifetime value across therapy areas”
The vertical (pharma/biopharma brands) is implied through Sanofi and therapy-area language, but the specific buyer role (e.g., VP of Patient Services, Brand GM) and company size/stage are never stated explicitly.
- 2
05Problem Leadership
“fewer than 1 in 3 patients still on a novel therapy at 12 months”
The page leads with the buyer's problem ... quantified therapy drop-off ... before explaining the solution, putting the pain front and center in the buyer's own reality.
- 2
06Solution Clarity
“unifies signals, programs, and interventions into one intelligent experience that keeps patients on therapy longer”
A visitor can repeat in one sentence what BrightInsight does: it unifies patient data and programs to prevent drop-off ... the solution is repeatable after a single read.
- 2
07Cost of Inaction
“$500B+ in annual value from brands every year”
The page explicitly names the financial cost of inaction ... $500B+ in annual brand value lost ... making the stakes concrete and quantified rather than abstract.
- 2
08Promised Land
“patients who stay on therapy longer, and brands that reclaim the revenue their science was built to generate”
The promised land is specific: patients persisting and brands recovering revenue ... a concrete, emotionally resonant after-state tied directly to the buyer's goals.
Trust Signal
4 signals
- 2
09Proof & Evidence
“reduced discontinuation by 4% and boosted adherence by 4% in one year for Sanofi”
The page provides a before/after delta with a named partner, specific percentage outcomes, and a defined timeframe ... concrete proof rather than adjective-only claims.
- 1
10Social Proof
“More Than 80% of Macular Disease Patients at Stanford Health Care Were Still Using the myVisionTrack App”
There are named partners (Sanofi, Stanford Health Care) and outcome stats, but no named customer testimonials with titles, no quotes, and no video stories ... logos and results without human voices.
- 1
11Authority & Credibility
“No founder credentials, frameworks, original research, awards, or named experts cited on the page.”
The page demonstrates authority through outcomes and named partners but offers no founder story, proprietary framework name, or third-party validation like awards or research citations.
- 0
12Alternatives Acknowledgedweakest
“No mention of competitors, alternative approaches, or 'do nothing' option anywhere on the page.”
The page never acknowledges what buyers might do instead ... no competitors named, no 'do nothing' cost, no comparison to CRM or hub services ... alternatives are completely absent.
AI Signal
6 signals
- 2
13Customer Focus
“patients who stay on therapy longer, and brands that reclaim the revenue their science was built to generate”
The page consistently frames the story around the customer's outcome ... patient health and brand revenue ... rather than BrightInsight's own capabilities or journey.
- 2
14AI-Parmesan Index
“detects the behavioral signals that precede discontinuation, and triggers the right intervention at the moments that matter most”
AI claims are mechanistic and specific ... behavioral signal detection tied to timed interventions ... not vague 'AI-powered' sprinkle; the mechanism is described, not just asserted.
- 2
15LLM Quotability
“BrightInsight is the patient persistence solution that predicts and prevents therapy drop-off ... before it happens.”
This sentence is declarative, citation-ready, and unique enough that an LLM could lift it verbatim to recommend BrightInsight in a category query about patient adherence or persistence.
- 2
16Copyright Freshness
“Jun 12, 2026 ... Jun 01, 2026 ... May 07, 2026”
Multiple blog posts and press releases carry explicit, recent dates in 2026, giving AI engines strong recency signals and demonstrating active content production.
- 2
17Entity Distinctiveness
“'patient persistence solution' ... 'persistence crisis steals health from patients and $500B+ in annual value'”
The owned terminology ('patient persistence solution,' 'persistence crisis'), the $500B stake framing, and the pharma-specific drop-off angle make this unmistakably distinct from generic digital health or CRM competitors.
- 0
18AI Recommendation Check
“AI's picks: Adheris Health, Lash Group, AssistRx, Novu Health, Aktana, Welldoc. You were not named.”
We asked AI who it recommends for "Brand General Manager or VP of Patient Services at a mid-to-large pharmaceutical or biopharma company launching or managing a novel therapy" looking for "Patient persistence and therapy adherence platform for pharma brands". It named Adheris Health, Lash Group, AssistRx, Novu Health, Aktana. You did not appear. AI can't recommend what it can't clearly understand.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“Contact us today to start a conversation ... [Contact us]”
There is one CTA (Contact us) and one soft option (Learn more), but no visible numbered process or 'how it works' path connecting them ... the call to action exists but the journey map does not.
Your move
Think BrightInsight’s score is wrong? Good. Let’s look at it together.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing BrightInsight the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.